| Literature DB >> 34041673 |
Qiong Yi1,2,3, Zhongcheng Liu1,2,3, Kun Zhang1,2,3, Xuening Liu1,2,3, Lifu Wang1,2,3, Bin Geng1,2,3, Yayi Xia4,5,6.
Abstract
Long non-coding RNA (lncRNA) is a type of non-coding RNA with length of nucleotides > 200 bp. Increasing evidences show that lncRNA breast cancer antiestrogen resistance 4 (BCAR4) plays an important role in the occurrence and development of various human cancers. It is found that BCAR4 is highly expressed in diverse tumor tissues and cells, and the high expression of BCAR4 is usually associated with poor prognosis. BCAR4 is considered as an oncogene in human cancers. By competing endogenous RNA (ceRNA) mechanism and regulating different signaling pathways, BCAR4 participates in the proliferation, apoptosis, migration, invasion, epithelial-mesenchymal transition (EMT), metastasis and tumorigenesis of different cancers. In addition, overexpression of BCAR4 promotes drug resistance of tumor cells. Therefore, BCAR4 is a promising biomarker for cancer diagnosis and prognosis, and it is a potential target for cancer therapy. This paper reviews studies focusing on the relationship between BCAR4 and cancers in recent years and aims to summarize the effect and mechanism of BCAR4 in human cancers.Entities:
Keywords: BCAR4; Biomarker; Cancer; Mechanism; lncRNA
Mesh：
Substances：
Year: 2021 PMID： 34041673 DOI： 10.1007/s13577-021-00556-6
Source DB: PubMed Journal: Hum Cell ISSN： 0914-7470 Impact factor: 4.174